Vir Historical Financial Ratios
| VIR Stock | USD 9.20 0.10 1.10% |
Vir Biotechnology is promptly reporting on over 121 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Price To Sales Ratio of 17.11, Dividend Yield of 0.0, PTB Ratio of 0.8 or Days Sales Outstanding of 208 will help investors to properly organize and evaluate Vir Biotechnology financial condition quickly.
Vir |
About Vir Financial Ratios Analysis
Vir BiotechnologyFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Vir Biotechnology investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Vir financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Vir Biotechnology history.
Vir Biotechnology Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Vir Biotechnology stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Vir Biotechnology sales, a figure that is much harder to manipulate than other Vir Biotechnology multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Most ratios from Vir Biotechnology's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Vir Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vir Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Vir Stock, please use our How to Invest in Vir Biotechnology guide.At this time, Vir Biotechnology's PTB Ratio is relatively stable compared to the past year. As of 02/27/2025, Book Value Per Share is likely to grow to 11.20, though Free Cash Flow Yield is likely to grow to (0.65).
| 2024 | 2025 (projected) | Payables Turnover | 0.5 | 0.48 | Days Of Inventory On Hand | 42.86 | 38.1 |
Vir Biotechnology fundamentals Correlations
Click cells to compare fundamentals
Vir Biotechnology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Vir Biotechnology fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 47.45 | 5.0 | 2.12 | 15.66 | 18.01 | 17.11 | |
| Ptb Ratio | 4.45 | 3.8 | 1.62 | 0.85 | 0.76 | 0.8 | |
| Book Value Per Share | 6.02 | 11.02 | 15.67 | 11.86 | 10.67 | 11.2 | |
| Free Cash Flow Yield | (0.0619) | (0.0128) | 0.48 | (0.59) | (0.68) | (0.65) | |
| Operating Cash Flow Per Share | (1.6) | (0.37) | 12.54 | (5.81) | (5.23) | (4.96) | |
| Stock Based Compensation To Revenue | 0.41 | 0.0771 | 0.0646 | 1.29 | 1.49 | 1.41 | |
| Capex To Depreciation | 1.2 | 3.75 | 10.03 | 1.11 | 1.0 | 0.95 | |
| Pb Ratio | 4.45 | 3.8 | 1.62 | 0.85 | 0.76 | 0.8 | |
| Ev To Sales | 41.95 | 4.81 | 1.67 | 14.3 | 16.44 | 15.62 | |
| Free Cash Flow Per Share | (1.66) | (0.53) | 12.03 | (5.97) | (5.37) | (5.1) | |
| Roic | (0.39) | (0.36) | 0.16 | 0.25 | (0.38) | (0.34) | |
| Net Income Per Share | (2.51) | 4.07 | 3.89 | (4.59) | (4.13) | (3.92) | |
| Payables Turnover | 59.4 | 10.1 | 22.78 | 0.44 | 0.5 | 0.48 | |
| Research And Ddevelopement To Revenue | 4.5 | 0.41 | 0.3 | 6.84 | 7.87 | 7.48 | |
| Capex To Revenue | 0.0974 | 0.0201 | 0.043 | 0.25 | 0.29 | 0.27 | |
| Cash Per Share | 6.18 | 5.45 | 18.11 | 11.35 | 10.22 | 5.44 | |
| Pocfratio | (16.71) | (114.28) | 2.02 | (1.73) | (1.99) | (2.09) | |
| Capex To Operating Cash Flow | (0.0343) | (0.46) | 0.0409 | (0.0277) | (0.0319) | (0.0334) | |
| Pfcf Ratio | (16.16) | (78.35) | 2.1 | (1.69) | (1.52) | (1.59) | |
| Days Payables Outstanding | 6.14 | 36.14 | 16.02 | 836.13 | 752.52 | 790.15 | |
| Income Quality | 0.64 | (0.09) | 3.22 | 1.27 | 1.14 | 0.86 | |
| Roe | (0.41) | (0.42) | 0.37 | 0.25 | (0.39) | (0.44) | |
| Ev To Operating Cash Flow | (14.77) | (109.77) | 1.58 | (1.58) | (1.82) | (1.91) | |
| Pe Ratio | (10.68) | 10.29 | 6.51 | (2.19) | (1.97) | (2.07) | |
| Return On Tangible Assets | (0.34) | 0.28 | 0.19 | (0.33) | (0.29) | (0.31) | |
| Ev To Free Cash Flow | (14.28) | (75.27) | 1.65 | (1.54) | (1.39) | (1.46) | |
| Earnings Yield | (0.0936) | 0.0972 | 0.15 | (0.46) | (0.52) | (0.5) | |
| Intangibles To Total Assets | 0.0552 | 0.0257 | 0.0177 | 0.0206 | 0.0237 | 0.0225 | |
| Net Debt To E B I T D A | 1.28 | (0.51) | (0.87) | 0.18 | 0.2 | 0.19 | |
| Current Ratio | 7.8 | 4.58 | 4.93 | 9.05 | 10.41 | 8.11 | |
| Tangible Book Value Per Share | 5.59 | 10.64 | 15.3 | 11.56 | 10.41 | 10.93 | |
| Graham Number | 18.42 | 31.77 | 37.03 | 34.97 | 31.48 | 16.53 | |
| Shareholders Equity Per Share | 6.02 | 11.02 | 15.67 | 11.86 | 10.67 | 11.2 | |
| Debt To Equity | 0.0928 | 0.0933 | 0.0616 | 0.0783 | 0.0705 | 0.036 | |
| Capex Per Share | 0.055 | 0.17 | 0.51 | 0.16 | 0.14 | 0.13 | |
| Graham Net Net | 4.49 | 5.93 | 12.65 | 8.9 | 8.01 | 8.41 | |
| Revenue Per Share | 0.56 | 8.37 | 11.92 | 0.64 | 0.58 | 0.55 | |
| Interest Debt Per Share | 0.56 | 1.03 | 2.35 | 0.93 | 0.84 | 0.66 | |
| Debt To Assets | 0.0724 | 0.0683 | 0.0457 | 0.0649 | 0.0584 | 0.0406 |
Pair Trading with Vir Biotechnology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vir Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vir Biotechnology will appreciate offsetting losses from the drop in the long position's value.Moving together with Vir Stock
Moving against Vir Stock
| 0.78 | INZY | Inozyme Pharma | PairCorr |
| 0.62 | KURA | Kura Oncology | PairCorr |
| 0.62 | ABOS | Acumen Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Vir Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vir Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vir Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vir Biotechnology to buy it.
The correlation of Vir Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vir Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vir Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vir Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Vir Stock Analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.